Reversible dementia—the implications of a fall in prevalence

544 13. Jacques PF, Felson DT, Tucker KL et al. Plasma 25-hydroxyvitamin D and its determinants in an elderly population sample. Am J Clin Nutr 1997; 66: 929–36. 14. van der Wielen RPJ, Lowik MRH, van den Berg H, de Groot LCPGM, Haller J, Morieras O. Serum vitamin D concentrations among elderly people in Europe. Lancet 1995; 346: 207–10. 15. Dhesi JK, Moniz C, Close JC, Allain TJ. A rationale for vitamin D prescribing in a falls clinic population. Age Ageing 2002; 31: 267–71. 16. Harwood RH, Sahota O, Gaynor K, Masud T, Hosking DJ. A randomised, controlled comparison of different calcium and vitamin D supplementation regimens in elderly women after hip fracture: The Nottingham Neck of Femur (NONOF) Study. Age Ageing 2004; 33: 45–51. 17. Veith R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations and safety. Am J Clin Nutr 1999; 69: 842–56. 18. Vasquez A, Manso G, Cannell J. The clinical importance of vitamin D (cholecalciferol): a paradigm shift with implications for all healthcare providers. Altern Ther Health Med 2004; 10: 28–36. 19. Armas LA, Hollis BW, Heaney RP. Vitamin D2 is much less effective than vitamin D3 in humans. Clin Endocrinol Metab 2004; 89: 5387–91. 20. Tilyard MW, Spears GF, Thomson J, Dovey S. Treatment of postmenopausal osteoporosis with calcitriol or calcium. N Engl J Med 1992; 6: 406–8. 21. Dukas L, Schacht E, Mazor Z, Stahelin HB. Treatment with alfacalcidol in elderly people significantly decreases the high risk of falls associated with a low creatinine clearance of <65 ml/min. Osteoporos Int 2004; 16: 198–203. 22. NICE. The secondary prevention of osteoporotic fracture in postmenopausal women. Technology Appraisal No. 87. DOH 2005.